Product image of Jublia (Efinaconazole) supplied by GNH India

Jublia

Active Ingredient:
Efinaconazole
Origin:
EU

Jublia (Efinaconazole)

Efinaconazole, the active ingredient in Jublia, is an azole antifungal presented as a 10% w/w topical solution for cutaneous use. It treats onychomycosis of the toenails in adult patients, improving nail appearance and reducing fungal infection.

GNH India supplies Jublia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP guidelines and provides reliable logistics for global distribution. Our portfolio includes a range of dermatological and antifungal products, ensuring consistent supply chain management and regulatory compliance.

Manufacturer / TM Owner

Almirall, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jublia (efinaconazole) is indicated for fungal nail infections (onychomycosis) affecting the toenails.

  • Onychomycosis of toenails: improves nail clarity and reduces fungal colonization.
  • Distal subungual onychomycosis: clears infection in the nail bed and surrounding tissue.
  • Proximal subungual onychomycosis: facilitates regrowth of healthy nail after fungal eradication.

How It Works

  • Efinaconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By blocking this pathway, the drug disrupts the formation of the fungal cell membrane, leading to increased membrane permeability and ultimately fungal cell death. This mechanism targets a broad spectrum of dermatophytes, yeasts and molds responsible for nail infection.

Side Effects

Efinaconazole topical solution may cause local skin reactions and, rarely, systemic hypersensitivity.

Common Side Effects

  • Application site irritation: redness or itching at the treated nail.
  • Burning sensation: mild transient heat feeling after application.
  • Dryness: peeling or flaking of surrounding skin.
  • Pruritus: localized itching around the nail.
  • Pain: discomfort during or after use.

Serious or Rare Side Effects

  • Allergic contact dermatitis: severe rash or swelling requiring medical attention.
  • Angioedema: rapid swelling of lips, face or throat.
  • Systemic fungal infection: unlikely but reported in immunocompromised patients.
  • Anaphylaxis: life‑threatening allergic reaction, emergency care needed.
  • Severe skin necrosis: rare tissue death at application site.

Precautions & Warnings

Before using Jublia, consider the following safety measures.

  • Pregnancy: safety not established; avoid use unless benefits outweigh risks.
  • Breastfeeding: unknown excretion; caution advised.
  • Renal impairment: no dosage adjustment required, but monitor for local irritation.
  • Application area: limit use to affected toenails only; avoid healthy skin.
  • Concomitant topical agents: do not combine with other antifungal creams to reduce irritation risk.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Efinaconazole may interact with other medications when applied to large skin areas or combined with systemic agents.

Major Interactions (Avoid)

  • Systemic azole antifungals (e.g., itraconazole, fluconazole): concurrent use may increase systemic exposure and toxicity.
  • Strong CYP3A4 inducers applied topically (e.g., ketoconazole shampoo): may reduce efinaconazole efficacy.

Moderate Interactions (Monitor Closely)

  • Other topical antifungal preparations: may increase local irritation.
  • Warfarin: extensive skin application could theoretically affect metabolism; monitor INR if large areas treated.
  • Immunosuppressants: monitor for potential increased risk of fungal infection despite treatment.

Frequently Asked Questions

Jublia is a prescription topical solution containing efinaconazole, indicated for the treatment of onychomycosis (fungal infection) of the toenails. It is applied directly to the affected nail(s) to eradicate the causative dermatophytes, improve nail appearance, and prevent further spread of the infection.

Efinaconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, which is essential for synthesizing ergosterol, a key component of the fungal cell membrane. By blocking this step, the drug compromises membrane integrity, leading to fungal cell death while concentrating the effect at the nail surface.

The prescribed regimen for Jublia is determined by the treating healthcare professional. Typically, a thin film of the 10 % solution is applied once daily to the affected toenail(s) after cleaning and drying the area. Patients should follow the specific instructions provided by their prescriber.

Safety data for efinaconazole in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and excretion in breast milk has not been established. Use is generally avoided unless the potential benefit justifies the potential risk, and the decision should be made by a qualified clinician.

To request Jublia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral antifungals such as terbinafine, Jublia offers a topical option that avoids systemic exposure and associated drug‑drug interactions. Relative to other topical agents like ciclopirox, efinaconazole demonstrates higher nail penetration and cure rates in clinical studies, though treatment duration remains similar.

Store Jublia at room temperature, below 25 °C, in its original container. Protect the solution from excessive heat, direct sunlight and moisture. Keep the cap tightly closed when not in use and keep out of reach of children.

Before each application, clean the affected toenail and surrounding skin, then dry thoroughly. Apply a thin layer of the 10 % solution to the nail surface and under the nail tip using the supplied applicator. Allow the medication to dry before putting on socks or shoes.

The most serious adverse reactions include allergic contact dermatitis, angioedema and, rarely, anaphylaxis. Patients should discontinue use and seek immediate medical attention if they experience severe swelling, rash, difficulty breathing or other signs of a systemic allergic response.

Jublia is contraindicated in individuals with known hypersensitivity to efinaconazole or any component of the formulation. It should also be avoided in patients with extensive skin disease on the application site or in those who are unable to comply with daily topical therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Efinaconazole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT